EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Three-Gene Xpert Host Response Signature for Pediatric Tuberculosis Screening: A Prospective Diagnostic Accuracy Study

Hayley Poore iD, Peter Wambi, Esin Nkereuwem iD, Jascent Nakafeero, Marie P Gomez, Moses Nsereko, Brittney Sweetser, Alfred Andama, Eric Wobudeya iD, Joel D Ernst iD, Adithya Cattamanchi, Devan Jaganath iD und 2 weitere

Clinical Infectious Diseases · 24.12.2025 · 81 (5) · e424-e431

DOI: 10.1093/cid/ciaf445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 21.08.2025. Verfasst von Hayley Poore und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Diseases & Critical Care Medicine, University of California, Irvine, Orange, California, USA. Hauptthemen laut MEDLINE: Tuberculosis, Pulmonary, Molecular Diagnostic Techniques, Mass Screening, Tuberculosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blood-based gene signatures offer potential as a near point-of-care tuberculosis (TB) screening tool. We examined the accuracy of the GeneXpert MTB Host Response (Xpert-HR) cartridge to screen for TB in children.

Methods

We enrolled children under 15 years from The Gambia and Uganda being evaluated for pulmonary TB. Each child provided a blood sample for Xpert-HR and underwent standard TB assessments, including chest X-ray (CXR) and sputum Xpert Ultra testing, followed by National Institutes of Health (NIH) case classification of Confirmed, Unconfirmed, or Unlikely TB. We measured cycle threshold (Ct) values for GBP5, DUSP3, and TBP, calculated an HR TB score, and generated ROC curves. Specificity was assessed at 90% sensitivity according to strict (SRS, Confirmed vs Unlikely TB), microbiological (MRS, Confirmed TB vs Unlikely or Unconfirmed TB), and composite (CRS, Confirmed or Unconfirmed TB vs Unlikely TB) reference standards compared with other TB evaluations.

Results

Among 181 children (median age 4 years; 53% female; 16% with HIV; 14.4% confirmed TB), the HR TB score cut-point of −0.65 showed 88.5% sensitivity with specificity at 33.3% (SRS) and 30.3% (MRS). Sensitivity was lower for the CRS at 75.7%, with similar specificity (33.3%). Sensitivity was higher in children aged 5–9 and 10–14 years compared with those under 5 years, but specificity remained low (22.7%–28.6%). Combining Xpert-HR with CXR, Xpert Ultra, or TB treatment decision algorithms did not significantly enhance accuracy.

Conclusions

GeneXpert MTB Host Response showed high sensitivity for detecting confirmed TB but had low specificity, risking overdiagnosis. Improved pediatric-specific gene signatures are necessary for better accuracy in children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, PulmonaryMolecular Diagnostic TechniquesMass ScreeningTuberculosisHumansChildChild, PreschoolFemaleMaleProspective StudiesAdolescentSensitivity and SpecificityInfantUgandaGambiaMycobacterium tuberculosisSputumROC Curve

Stichwörter der Autor:innen

biomarkerchilddiagnosticscreeningtuberculosis

Autor:innen und Institutionen

  • Division of Pulmonary Diseases & Critical Care Medicine, University of California, Irvine, Orange, California, USA.
  • Center for Tuberculosis, Institute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA.
  • World Alliance for Lung and Intensive Care Medicine in Uganda (Walimu), Kampala, Uganda.
  • Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia.
  • Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Division of Pediatric Infectious Diseases, University of California, San Francisco, San Francisco, California, USA.

ORCID-Profile: Hayley Poore, Esin Nkereuwem, Eric Wobudeya, Joel D Ernst, Devan Jaganath

Förderung

  • NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Poore, H., Wambi, P., Nkereuwem, E., Nakafeero, J., Gomez, M. P., Nsereko, M., Sweetser, B., Andama, A., Wobudeya, E., Ernst, J. D., Cattamanchi, A., Jaganath, D., Kampmann, B., & COMBO Study (2025). The Three-Gene Xpert Host Response Signature for Pediatric Tuberculosis Screening: A Prospective Diagnostic Accuracy Study. Clinical Infectious Diseases, 81(5), e424-e431. https://doi.org/10.1093/cid/ciaf445

Vancouver

Poore H, Wambi P, Nkereuwem E, Nakafeero J, Gomez MP, Nsereko M, et al. The Three-Gene Xpert Host Response Signature for Pediatric Tuberculosis Screening: A Prospective Diagnostic Accuracy Study. Clinical Infectious Diseases. 2025;81(5):e424-e431. doi:10.1093/cid/ciaf445

BibTeX
@article{Poore2025,
  author = {Poore, Hayley and Wambi, Peter and Nkereuwem, Esin and Nakafeero, Jascent and Gomez, Marie P and Nsereko, Moses and Sweetser, Brittney and Andama, Alfred and Wobudeya, Eric and Ernst, Joel D and Cattamanchi, Adithya and Jaganath, Devan and Kampmann, Beate and COMBO Study, COMBO Study},
  title = {The Three-Gene Xpert Host Response Signature for Pediatric Tuberculosis Screening: A Prospective Diagnostic Accuracy Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {5},
  pages = {e424--e431},
  doi = {10.1093/cid/ciaf445}
}
Kostenlos starten →